AlphaQuest LLC Has $229,000 Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

AlphaQuest LLC lessened its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 70.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 8,575 shares of the company’s stock after selling 20,307 shares during the quarter. AlphaQuest LLC’s holdings in Amphastar Pharmaceuticals were worth $229,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC increased its position in shares of Amphastar Pharmaceuticals by 356.0% during the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock worth $25,000 after buying an additional 737 shares during the period. Global Retirement Partners LLC grew its holdings in Amphastar Pharmaceuticals by 219.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock worth $27,000 after acquiring an additional 703 shares during the period. Hantz Financial Services Inc. raised its position in shares of Amphastar Pharmaceuticals by 3,430.8% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock worth $32,000 after acquiring an additional 1,338 shares in the last quarter. IFP Advisors Inc lifted its stake in shares of Amphastar Pharmaceuticals by 75.7% in the 2nd quarter. IFP Advisors Inc now owns 2,035 shares of the company’s stock valued at $52,000 after purchasing an additional 877 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Amphastar Pharmaceuticals by 263.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,583 shares of the company’s stock valued at $82,000 after purchasing an additional 2,596 shares during the period. Institutional investors own 65.09% of the company’s stock.

Insider Activity at Amphastar Pharmaceuticals

In related news, Director Richard K. Prins sold 4,179 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $27.10, for a total transaction of $113,250.90. Following the completion of the sale, the director owned 35,183 shares in the company, valued at approximately $953,459.30. This trade represents a 10.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Rong Zhou sold 9,787 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $26.20, for a total transaction of $256,419.40. Following the completion of the sale, the executive vice president directly owned 138,043 shares in the company, valued at approximately $3,616,726.60. This represents a 6.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 34,808 shares of company stock worth $919,002. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Stock Down 0.1%

AMPH stock opened at $28.57 on Wednesday. The firm has a market capitalization of $1.31 billion, a PE ratio of 12.64, a P/E/G ratio of 5.07 and a beta of 0.88. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78. Amphastar Pharmaceuticals, Inc. has a twelve month low of $20.39 and a twelve month high of $32.69. The stock’s 50 day moving average is $26.91 and its 200-day moving average is $26.59.

Analyst Ratings Changes

AMPH has been the topic of several recent analyst reports. Needham & Company LLC dropped their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Barclays began coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price objective for the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 29th. Finally, Zacks Research cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 14th. Two research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals has an average rating of “Hold” and a consensus price target of $31.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.